Now showing items 1-3 of 3
Osteoprotegerin and breast cancer risk by hormone receptor subtype: A nested case-control study in the EPIC cohort
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-02-08)
Background:<br>Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study.<br>Methods:<br>A case-control ...
Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort.
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-08-31)
Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has ...
Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: A nested case-control study
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-04-04)
Background:<br>Leakage of bacterial products across the gut barrier may play a role in liver diseases which often precede the development of liver cancer. However, human studies, particularly from prospective settings, are lacking.<br>Methods:<br>We used a case-control study design nested within a large prospective cohort to assess the association between circulating levels of anti-lipopolysaccharide ...